Literature DB >> 22921847

Maternal and neonatal copeptin levels at cesarean section and vaginal delivery.

Ashraf A Foda1, Ibrahim A Abdel Aal.   

Abstract

OBJECTIVE: The objective of the study was to measure the copeptin levels in maternal serum and umbilical cord serum at cesarean section and vaginal delivery in normotensive pregnancy and pre-eclamptic women. STUDY
DESIGN: This was a prospective study at Mansoura University Hospital, Egypt. Ninety cases were included. They were divided into six groups: (1) normal pregnancy near term, as a control group, (2) primiparas who had vaginal delivery, (3) primiparas who had vaginal delivery and mild preeclampsia, (4) elective repeat cesarean section, (5) intrapartum cesarean section for indications other than fetal distress, and (6) intrapartum cesarean section for fetal distress. Serum copeptin concentrations were quantified with an enzyme-linked immunosorbent assay (ELISA). Mean, standard deviation, and paired t-test were used to test for significant change in quantitative data.
RESULTS: The vaginal delivery groups had higher levels of maternal serum copeptin than the elective cesarean section group (P<0.01). Higher maternal serum copeptin levels were found in cases with pre-eclampsia as compared with the normotensive cases. The maternal copeptin levels during intrapartum cesarean section were higher than that during elective repeat cesarean section. There was a significant correlation between maternal copeptin levels and the duration of the first stage. In the presence of fetal distress, umbilical cord serum copeptin levels were significantly higher than other groups.
CONCLUSION: Vaginal delivery can be very painful and stressful, and is accompanied by a marked increase of maternal serum copeptin. Increased maternal levels of serum copeptin were found in cases with pre-eclampsia as compared with the normotensive cases, and it may be helpful in assessing the disease. Intrauterine fetal distress is a strong stimulus to the release of copeptin into the fetal circulation.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22921847     DOI: 10.1016/j.ejogrb.2012.08.012

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  14 in total

Review 1.  Vasopressin: the missing link for preeclampsia?

Authors:  Jeremy A Sandgren; Sabrina M Scroggins; Donna A Santillan; Eric J Devor; Katherine N Gibson-Corley; Gary L Pierce; Curt D Sigmund; Mark K Santillan; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-03-25       Impact factor: 3.619

2.  Angiotensin AT1A receptors expressed in vasopressin-producing cells of the supraoptic nucleus contribute to osmotic control of vasopressin.

Authors:  Jeremy A Sandgren; Danny W Linggonegoro; Shao Yang Zhang; Sarah A Sapouckey; Kristin E Claflin; Nicole A Pearson; Mariah R Leidinger; Gary L Pierce; Mark K Santillan; Katherine N Gibson-Corley; Curt D Sigmund; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-01-24       Impact factor: 3.619

Review 3.  Hypertension in Pregnancy: Defining Blood Pressure Goals and the Value of Biomarkers for Preeclampsia.

Authors:  Pitchaphon Nissaisorakarn; Sairah Sharif; Belinda Jim
Journal:  Curr Cardiol Rep       Date:  2016-12       Impact factor: 2.931

4.  Selective Serotonin Reuptake Inhibitor Use in Pregnancy and Protective Mechanisms in Preeclampsia.

Authors:  Julie A Vignato; S Banu Gumusoglu; Heather A Davis; Sabrina M Scroggins; Wendy S Hamilton; Debra S Brandt; Gary L Pierce; Boyd A Knosp; Donna A Santillan; Mark K Santillan
Journal:  Reprod Sci       Date:  2022-08-19       Impact factor: 2.924

5.  Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice.

Authors:  Jeremy A Sandgren; Guorui Deng; Danny W Linggonegoro; Sabrina M Scroggins; Katherine J Perschbacher; Anand R Nair; Taryn E Nishimura; Shao Yang Zhang; Larry N Agbor; Jing Wu; Henry L Keen; Meghan C Naber; Nicole A Pearson; Kathy A Zimmerman; Robert M Weiss; Noelle C Bowdler; Yuriy M Usachev; Donna A Santillan; Matthew J Potthoff; Gary L Pierce; Katherine N Gibson-Corley; Curt D Sigmund; Mark K Santillan; Justin L Grobe
Journal:  JCI Insight       Date:  2018-10-04

6.  Elevated vasopressin in pregnant mice induces T-helper subset alterations consistent with human preeclampsia.

Authors:  Sabrina M Scroggins; Donna A Santillan; Jenna M Lund; Jeremy A Sandgren; Lindsay K Krotz; Wendy S Hamilton; Eric J Devor; Heather A Davis; Gary L Pierce; Katherine N Gibson-Corley; Curt D Sigmund; Justin L Grobe; Mark K Santillan
Journal:  Clin Sci (Lond)       Date:  2018-02-14       Impact factor: 6.124

7.  Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model.

Authors:  Mark K Santillan; Donna A Santillan; Sabrina M Scroggins; James Y Min; Jeremy A Sandgren; Nicole A Pearson; Kimberly K Leslie; Stephen K Hunter; Gideon K D Zamba; Katherine N Gibson-Corley; Justin L Grobe
Journal:  Hypertension       Date:  2014-07-07       Impact factor: 10.190

8.  Increased levels of copeptin before clinical diagnosis of preeclampsia.

Authors:  Edwina H Yeung; Aiyi Liu; James L Mills; Cuilin Zhang; Tuija Männistö; Zhaohui Lu; Michael Y Tsai; Pauline Mendola
Journal:  Hypertension       Date:  2014-09-15       Impact factor: 10.190

9.  Copeptin: a new biomarker that is specific for preeclampsia?

Authors:  Denise C Cornelius
Journal:  Hypertension       Date:  2014-09-15       Impact factor: 10.190

10.  Copeptin in Patients with Pregnancy-Induced Hypertension.

Authors:  Agnieszka Marek; Rafał Stojko; Agnieszka Drosdzol-Cop
Journal:  Int J Environ Res Public Health       Date:  2021-06-15       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.